OBJECTIVES: Elevated blood cholesterol levels are a major risk factor for coronary artery disease, the leading cause of death worldwide. Probiotics have been investigated as potential cholesterol-lowering therapies, but no previous studies have assessed the effect of the probiotic yeast Saccharomyces boulardii on cholesterol levels in human volunteers. The objective of this study was to examine the effect of S. boulardii on serum cholesterol and lipoprotein particles in hypercholesterolemic adults. DESIGN: This study was a single-arm, open-label pilot study. SUBJECTS: Twelve hypercholesterolemic participants were recruited into the study; one dropped out. INTERVENTION: Participants took 5.6×10(10) colony forming unit (CFU) encapsulated S. boulardii (Saccharomyces cerevisiae var. boulardii CNCM I-1079) twice daily for an 8-week period. OUTCOME MEASURES: Fasting concentrations of cholesterol (total cholesterol, low-density lipoprotein-cholesterol [LDL-C], high-density lipoprotein-cholesterol [HDL-C], and triglycerides), lipoprotein particles (very-low-density lipoprotein-particle [VLDL-P], remnant lipoprotein particle [RLP-P], total LDL-P, LDL III-P, LDL IV-P, total HDL-P, and HDL 2b-P), and additional cardiovascular biomarkers (apo B-100, lipoprotein [a], high-sensitivity C-reactive protein, homocysteine, fibrinogen, and insulin) were measured at baseline, after 4 weeks, and after 8 weeks. RESULTS: Remnant lipoprotein particles decreased by 15.5% (p=0.03) over the 8-week period. The remaining outcome measures were not significantly altered. CONCLUSIONS: In this pilot study, 8 weeks of daily supplementation with S. boulardii lowered remnant lipoprotein, a predictive biomarker and potential therapeutic target in the treatment and prevention of coronary artery disease.
OBJECTIVES: Elevated blood cholesterol levels are a major risk factor for coronary artery disease, the leading cause of death worldwide. Probiotics have been investigated as potential cholesterol-lowering therapies, but no previous studies have assessed the effect of the probiotic yeastSaccharomyces boulardii on cholesterol levels in human volunteers. The objective of this study was to examine the effect of S. boulardii on serum cholesterol and lipoprotein particles in hypercholesterolemic adults. DESIGN: This study was a single-arm, open-label pilot study. SUBJECTS: Twelve hypercholesterolemicparticipants were recruited into the study; one dropped out. INTERVENTION: Participants took 5.6×10(10) colony forming unit (CFU) encapsulated S. boulardii (Saccharomyces cerevisiae var. boulardii CNCM I-1079) twice daily for an 8-week period. OUTCOME MEASURES: Fasting concentrations of cholesterol (total cholesterol, low-density lipoprotein-cholesterol [LDL-C], high-density lipoprotein-cholesterol [HDL-C], and triglycerides), lipoprotein particles (very-low-density lipoprotein-particle [VLDL-P], remnant lipoprotein particle [RLP-P], total LDL-P, LDL III-P, LDL IV-P, total HDL-P, and HDL 2b-P), and additional cardiovascular biomarkers (apo B-100, lipoprotein [a], high-sensitivity C-reactive protein, homocysteine, fibrinogen, and insulin) were measured at baseline, after 4 weeks, and after 8 weeks. RESULTS: Remnant lipoprotein particles decreased by 15.5% (p=0.03) over the 8-week period. The remaining outcome measures were not significantly altered. CONCLUSIONS: In this pilot study, 8 weeks of daily supplementation with S. boulardii lowered remnant lipoprotein, a predictive biomarker and potential therapeutic target in the treatment and prevention of coronary artery disease.
Authors: James D Otvos; Samia Mora; Irina Shalaurova; Philip Greenland; Rachel H Mackey; David C Goff Journal: J Clin Lipidol Date: 2011 Mar-Apr Impact factor: 4.766
Authors: William C Cromwell; James D Otvos; Michelle J Keyes; Michael J Pencina; Lisa Sullivan; Ramachandran S Vasan; Peter W F Wilson; Ralph B D'Agostino Journal: J Clin Lipidol Date: 2007-12 Impact factor: 4.766
Authors: K Kugiyama; H Doi; T Motoyama; H Soejima; K Misumi; H Kawano; O Nakagawa; M Yoshimura; H Ogawa; T Matsumura; S Sugiyama; T Nakano; K Nakajima; H Yasue Journal: Circulation Date: 1998-06-30 Impact factor: 29.690
Authors: Michał Seweryn Karbownik; Joanna Kręczyńska; Paulina Kwarta; Magdalena Cybula; Anna Wiktorowska-Owczarek; Edward Kowalczyk; Tadeusz Pietras; Janusz Szemraj Journal: Nutrients Date: 2020-05-19 Impact factor: 5.717
Authors: Jimmy G Hernández-Gómez; Argelia López-Bonilla; Gabriela Trejo-Tapia; Sandra V Ávila-Reyes; Antonio R Jiménez-Aparicio; Humberto Hernández-Sánchez Journal: Foods Date: 2021-03-22
Authors: Jalal Moludi; Mohammad Alizadeh; Ned Lotfi Yagin; Yahiya Pasdar; Seyed Mostafa Nachvak; Hadi Abdollahzad; Ali Sadeghpour Tabaei Journal: J Cardiovasc Thorac Res Date: 2018-09-27